AstraZeneca PLC
AZNCF
$147.38
-$0.745-0.50%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 54.07B | 51.21B | 49.13B | 47.61B | 45.81B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.07B | 51.21B | 49.13B | 47.61B | 45.81B |
| Cost of Revenue | 9.64B | 8.91B | 8.54B | 8.33B | 8.04B |
| Gross Profit | 44.44B | 42.30B | 40.59B | 39.28B | 37.77B |
| SG&A Expenses | 19.45B | 18.08B | 18.27B | 18.37B | 18.03B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -190.00M | -220.00M | -265.00M | -989.00M | -1.02B |
| Total Operating Expenses | 41.17B | 38.34B | 37.63B | 36.55B | 35.52B |
| Operating Income | 12.91B | 12.87B | 11.51B | 11.06B | 10.29B |
| Income Before Tax | 8.69B | 7.92B | 7.75B | 7.44B | 6.90B |
| Income Tax Expenses | 1.65B | 1.42B | 1.30B | 1.10B | 938.00M |
| Earnings from Continuing Operations | 7.04K | 6.50K | 6.45K | 6.34K | 5.96K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -6.00M | -5.00M | -5.00M | -6.00M | -6.00M |
| Net Income | 7.04B | 6.50B | 6.44B | 6.33B | 5.96B |
| EBIT | 12.91B | 12.87B | 11.51B | 11.06B | 10.29B |
| EBITDA | 17.55B | 17.58B | 16.13B | 15.66B | 14.87B |
| EPS Basic | 4.54 | 4.19 | 4.16 | 4.09 | 3.84 |
| Normalized Basic EPS | 4.69 | 4.69 | 4.13 | 3.94 | 3.64 |
| EPS Diluted | 4.51 | 4.16 | 4.13 | 4.06 | 3.82 |
| Normalized Diluted EPS | 4.66 | 4.65 | 4.10 | 3.91 | 3.62 |
| Average Basic Shares Outstanding | 6.20B | 6.20B | 6.20B | 6.20B | 6.20B |
| Average Diluted Shares Outstanding | 6.24B | 6.24B | 6.24B | 6.24B | 6.24B |
| Dividend Per Share | 3.10 | 2.97 | 2.97 | 2.90 | 2.90 |
| Payout Ratio | 65.80% | 71.25% | 69.29% | 70.56% | 75.25% |
